Journal
CLINICAL & EXPERIMENTAL METASTASIS
Volume 34, Issue 1, Pages 1-10Publisher
SPRINGER
DOI: 10.1007/s10585-016-9831-9
Keywords
Bone pain palliation; Bone-seeking radiopharmaceuticals; Radiolabeled phosphonates; (Na3PO4)-P-32; (SrCl2)-Sr-89; Sn-117m-DTPA; (RaCl2)-Ra-223
Categories
Funding
- Government of India
Ask authors/readers for more resources
Bone pain arising due to skeletal metastases is one of the common complications experienced by the majority of patients suffering from prostate, breast and lung cancer at the advanced stage of the disease. These patients are subjected to palliative care in order to improve the quality of their remaining life. With the gradually increasing number of cancer cases, palliation of metastatic bone pain is gaining importance. Bone-seeking radiopharmaceuticals play a pivotal role in the management of cancer pain, particularly in patients with multiple metastases, as these agents are proven to be effective in controlling the bone pain with minimum side effects. Although a plethora of such radiopharmaceuticals have been developed and evaluated in animal models, only a few are regularly used in clinics while some of these agents are at different stages of clinical evaluations. The present article describes only those bone-seeking radiopharmaceuticals, which have been reported to be clinically administered till date, along with their relative merits and drawbacks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available